debate: should you use third-line (salvage) therapy to manage patients with advanced nsclc? - no
Published 10 years ago • 52 plays • Length 7:33Download video MP4
Download video MP3
Similar videos
-
11:55
debate: should you use third-line (salvage) therapy to manage patients with advanced nsclc? - yes
-
14:39
debate: adjuvant therapy for resected node negative stage i nsclc? - sometimes
-
7:24
debate: surgery for stage iiia patients with lung cancer? - no
-
12:41
debate: surgery for stage iiia patients with lung cancer? - yes
-
9:37
do you need hormonal therapy to treat breast cancer?
-
4:15
cure for lung cancer? study finds new pill cuts risk of death | vantage with palki sharma
-
4:05
keeping lung cancer under control: bob's immunotherapy story
-
9:27
debate: should immunotherapy be used alone? - no, only in combination with chemotherapy
-
10:45
debate: adjuvant egfr-directed therapy for patients with early stage nsclc? - no
-
19:51
debate: should immunotherapy be used alone? - yes, immunotherapy could be used alone
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
13:26
debate: drug of choice for exon 19 del egfr mutant nsclc - any egfr tki
-
11:05
debate: what is the optimal chemotherapy for stage iii nsclc? - taxane/carboplatin is the standard
-
7:21
second- & third-line options after chemotherapy or i/o
-
10:45
debate: what is the optimal chemotherapy for stage iii nsclc? - cisplatin/etoposide is the standard
-
11:38
debate: alk positive nsclc - front line therapy - ceritinib
-
17:30
immunotherapy in lung cancer: panacea vs. reality?
-
20:35
maintenance paradigm in non-squamous nsclc
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
3:56
key next steps after a lung cancer diagnosis: expert advice
-
0:22
detect lung cancer early